Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ...

A new Apple-backed AI model trained on Apple Watch behavioral data can now predict a wide range of health conditions more accurately than traditional sensor-based approaches, according to a ...

Based on the positive Phase 1 data, Artelo plans to initiate a Multiple Ascending Dose or MAD study in the fourth quarter of 2025 to further evaluate ART26.12 with repeated dosing over time.